SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

BioPharmX Corp. (BPMX)

Add BPMX Price Alert      Hide Sticky   Hide Intro
Moderator: Whos_Who
Search This Board:
Last Post: 1/18/2017 1:35:37 PM - Followers: 33 - Board type: Free - Posts Today: 0


Biodelivery that makes a difference! 

We develop unique health and wellness products for licensing and commercialization in pharmaceutical and over-the-counter use.



By design, BioPharmX's innovative drug delivery products, with their unique patented platform technologies, are formulated to address the needs of well-defined, fast-growing, multi-billion dollar markets, including dermatology, aesthetics, otolaryngology (ears, nose & throat), and women’s health.

BioPharmX currently has multiple products in various stages of development in all three of these markets, but its first commercialized product will be a woman’s breast health product launching in January 2015.


  Delivery Pathways

  BioPharmX creates unique drug delivery products for IP licensing or direct commercialization for pharmaceutical, over-the-counter, and supplement distribution and sales.

Product Types

Our unique health and wellness products (for licensing and commercialization in pharmaceutical and over-the-counter (OTC) use) leverage our extensive experience in pharmacological and biological sciences and drug delivery product development. Our team is experienced in performing pre-clinical studies focused on analytics, pharmacokinetics and toxicology, experimental design, and investigational protocols. We do this through product research and development and through strategic partnerships with leading worldwide pharmaceutical companies.

Our commitment to providing customers with products that improve the quality of their lives can only be met through unrivaled innovation and a dedication to quality—both of which are integral parts of BioPharmX's company culture.


            Over the Counter Products        


With significant investments in R&D and a deep background in pharmaceutical and medical device development, BioPharmX is uniquely positioned to bring leading-edge, over-the-counter (OTC) products to the retail marketplace. Our products all meet rigorous internal quality measurements and leverage the capabilities required for pharmaceutical grade FDA products. 


BioPharmX enables innovative solutions by working with pharmaceutical companies worldwide to achieve shorter time-to-market scenarios. We do this through a suite of core competencies unique to our teams:

♦ Customized solutions to fit drug formulation needs
♦ Expertise in regulatory, toxicology and clinical studies
♦ Streamlined pathways through development
♦ Unrivaled commitment to quality





BioPharmX currently has multiple products in various stages of development for therapeutic drug delivery in the areas of women's health, dermatology, aesthetics and ENT.




Our R&D team specializes in developing world-class clinical studies. They perform formulation development, outline safety profiles and dosing requirements, and set validation protocols. Currently they are developing a portfolio of patented drug applications (including novel formulations and minimally invasive delivery devices in respective markets) to be out-licensed or commercialized.


"Biopharmx's first product violet will hit market this fall"
"This company is a $$ maker." 




BioPharmX partners with leading pharmaceutical companies through regulatory approval or performs all activities internally, utilizing our team of regulatory and product development experts. Our partners turn to us to enhance delivery characteristics to improve drug performance and patient compliance. Our proven methods and technologies provide our customers with unique and measurable technical and competitive advantages.



Management Team

The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.



Jim Pekarsky                                                                                                                          

Mr. Pekarsky has devoted over 30 years to growing diverse medical research and high-tech companies, including Bio Rad Laboratories, Mentor Graphics, MoSys and Virage Logic. He has spent over 10 years as the Chief Financial Officer of several public and private companies and five years as a European General Manager for U.S. multinational corporations. For more than a decade he has been counseling start-ups in Silicon Valley and leading their financings, acquisitions and initial public offerings. Pekarsky holds an M.B.A. in finance from Golden Gate University in San Francisco and a bachelor’s degree in accounting from Indiana University of Pennsylvania.


Anja Krammer                                                                                                                                    

A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.

Kin F. Chan, Ph.D.                                                                                                                             

Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, Chan was Vice President of Engineering at Demira, where he helped develop photodynamic therapies and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.

Douglas Thomas, Ph.D.                                                                                                                     

Dr. Thomas has more than 20 years of experience in biopharmaceutical research, process development, manufacturing and commercial development in start-ups and Fortune 500 companies. His background includes 10 years in business development and more than 10 years in research and development. He has consulted extensively in innovative start-ups focused on the application of diverse hardware and software in the biopharmaceutical industry. He has worked with a variety of biomedical companies, including BioSys Laboratories, Calypte Biomedical, Millipore and Invitrogen Life Technologies. Thomas holds a Ph.D. in immunology from Baylor College of Medicine and a bachelor’s degree in pharmacology from the University of California, Santa Barbara.

Jack Kessler, Ph.D.                                                                                                                           

Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.

AnnaMarie Daniels                                                                                                                             

Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.

Ross Portaro                                                                                                                                     

Mr. Portaro has 30 years of global sales executive experience in dermatology, women's health, and aesthetics. In dermatology, most recently as a sales director at Ulthera, he doubled sales and positioned them for their 2014 acquisition by Merz. At Medicis, Portaro led the LipoSonix team in Europe and facilitated the sale to Solta in 2011. In Women's Health, he built the original sales team at SenoRx, which was the leader in breast biopsies devices and had a successful 2007 IPO. In aesthetics, Mr. Portaro started TRIA Beauty as the Vice President of Sales and was the first medical laser executive to globally launch a medical-grade laser for hair removal into the consumer OTC Market. TRIA Beauty is positioned for a 2014 IPO. Mr. Portaro received his BS in Commerce from the McIntyre School of Commerce at the University of Virginia.
Stephen Morlock                                                                                                                                    
A seasoned financial executive and retail industry veteran, has been added to its board of directors.  Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.

Morlock previously served as executive vice president and chief financial officer from 1994 to 2004 at Otis Spunkmeyer, a baked goods distribution company that has successfully pursued distribution of its products to small family-owned businesses all the way up to large worldwide organizations, including the U.S. Army.  He served as controller there from 1992 to 1994.  He also has experience garnered from these roles in various aspects of the retail industry, including going to market via various distribution channels, product merchandizing, customer relationship management, brand development, manufacturing, procurement, and inventory management.   

"Stephen brings a unique blend of financial expertise and experience in the retail industry to BioPharmX," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX Corporation.  "His expertise and experience will prove valuable as we continue retail distribution expansion for Violet iodine."

Prior to his roles at Otis Spunkmeyer, Morlock held various management positions in accounting, financial planning and internal auditing at Westinghouse Electric Supply Company from 1977 to 1991. He holds a B.S. degree in Accounting from San Diego State University


Corporate Headquarters

BioPharmX, Inc.
1098 Hamilton Court
Menlo Park, CA 94025

SEC Filings link below.

OneMed San Francisco 2014 Webcast

2015 Second Quater Finacial Results Webcast






  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Statement of Changes in Beneficial Ownership (4) 01/20/2017 06:13:33 PM
#225  Sticky Note BioPharmX BPMX Corporate Presentation Whos_Who 05/20/16 04:54:52 PM
#358   Has anyone any information on how things went scubagallag 01/18/17 01:35:36 PM
#357   Happy New Year to you! Glad to see Whos_Who 01/14/17 04:26:36 PM
#356   Happy new year ! THEBELGIAN77 01/14/17 10:30:18 AM
#355   BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Whos_Who 01/12/17 09:43:07 AM
#354   "Many in the dermatology community look forward to Whos_Who 01/09/17 09:58:20 AM
#353   When do you expect the results March? I'm HUBMASTER 01/08/17 09:54:32 PM
#352   BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Whos_Who 01/04/17 09:38:19 AM
#351   Reversal confirmed!!!! Lets go BPMX!!!!!!!! HUBMASTER 12/22/16 07:07:13 PM
#350 HUBMASTER 12/22/16 07:05:02 PM
#349   That's great, you're still here! As soon as Whos_Who 12/21/16 12:29:51 PM
#348   Love this stock. I am on OPGN also DrShocker 12/21/16 11:45:02 AM
#347   DrShocker, you still in the house? Haven't seen Whos_Who 12/20/16 09:58:26 PM
#346   BELGIAN77, you still with us? Big things around Whos_Who 12/20/16 09:45:45 PM
#345   Great news! New lab and office space. Ramping up! diehard2 12/20/16 09:46:24 AM
#344   Hi ClayTrader, are the bulls still in charge? diehard2 12/19/16 10:59:40 AM
#343   RESEARCH REPORT UPDATE Whos_Who 12/18/16 08:31:15 PM
#342   "The new financing immediately boosted the company s Whos_Who 12/18/16 08:26:44 PM
#341   * * $BPMX Video Chart 12-15-16 * * ClayTrader 12/15/16 05:16:47 PM
#340   * * $BPMX Video Chart 12-14-16 * * ClayTrader 12/14/16 05:17:39 PM
#339   Might jump in here at eod Ross92 12/14/16 03:50:09 PM
#338   BioPharmX Corporation Reports Third Quarter Financial Results Whos_Who 12/13/16 04:09:39 PM
#337   Anyone revisiting BPMX this week? TheHungryHippo 12/11/16 11:21:32 PM
#336   Too oversold, had to correct itself. Whos_Who 12/08/16 12:43:07 PM
#335   15-min Ichimoku looking real nice Johndonceal 12/08/16 12:15:15 AM
#334   BPMX .60s boom! ClearlyStocks 12/07/16 05:14:26 PM
#333   Alive and strong!! Looking forward to 3Q earnings Whos_Who 12/07/16 04:37:44 PM
#332   What a beauty. Broke .50 and flew as planned ClearlyStocks 12/07/16 04:19:01 PM
#331   BioPharmX to present evidence that BPX-01 topical minocycline Whos_Who 12/07/16 09:30:05 AM
#330   BioPharmX to Report Third Quarter Financial Results Whos_Who 12/06/16 09:42:46 AM
#329   BioPharmX Presents Research at Cell Biology 2016 Showing Whos_Who 12/05/16 09:29:55 AM
#328   "do you know if the purchases were made Whos_Who 12/02/16 09:15:26 PM
#327   These purchases by Vivo Capital VIII, LLC, Franklin bogblog 12/02/16 08:46:32 PM
#326   * * $BPMX Video Chart 12-02-16 * * ClayTrader 12/02/16 05:05:20 PM
#325   Vivo Capital VIII, LLC claims to own 12,814,286 Whos_Who 12/02/16 03:23:02 PM
#324   Activist investor FRANKLIN RESOURCES INC just increased their wiltonio 12/02/16 11:13:50 AM
#323   BioPharmX Poster at ASCB Annual Meeting to Show Whos_Who 12/01/16 09:13:28 AM
#322   Director Stephen Morlock purchased 428,571 shares of the Whos_Who 11/30/16 09:48:04 AM
#321   BioPharmX Corporation Announces Closing of a $12.5 Million Whos_Who 11/28/16 05:11:30 PM
#320   How about the massive Vol increase the last Whos_Who 11/25/16 07:11:35 PM
#319   BPMX bullish 0.3515 stocktrademan 11/21/16 03:51:41 PM
#318   BPMX up to $2 ??? It will be pennyroller16 11/15/16 11:39:15 PM
#317   Correction, 24 week study from Aug 24th Whos_Who 11/15/16 10:11:22 PM
#316   The PR on watch is the phase 2b Whos_Who 11/15/16 08:28:22 PM
#315   When are they going to release another PR louisgeorge 11/15/16 05:40:28 PM
#314   negative as if they keep offing private deals scubagallag 11/15/16 11:24:36 AM
#313   what a POS stock this is. They got scubagallag 11/15/16 11:22:08 AM
#312   Sessions: SDEF’s 17th Las Vegas Dermatology Seminar Whos_Who 11/10/16 12:34:53 PM
#311   BioPharmX will present results from two clinical studies Whos_Who 11/10/16 09:52:13 AM
#310   BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data Whos_Who 11/10/16 09:08:33 AM
#309   They better stop the BS and price the ErnieBilco 11/09/16 04:16:49 PM